

Poster Session

Chair: Yasuo Ariumi & Yorifumi Satou

Session I : October 30, Wednesday 13:00-15:00

Odd numbers: 13:00-14:00 / Even numbers: 14:00-15:00

Session II : October 31, Thursday 12:05-14:00

Free Time (Light snacks will be served)

Aso Resort GRANDVRIO Hotel

※ The poster numbers highlighted in blue make 1-minute presentation.

※ The poster numbers highlighted in green make oral presentation on 31st October.

Poster No.	Presenter	Title
P-01	Kouki Matsuda [Kumamoto Univ.]	Inhibition of HIV-1 entry by a tricyclic coumarin GUT-70
P-02 O-35-3B	Ryusho Kariya [Kumamoto Univ.]	HAMLET and BAMLET induces cell death of Primary Effusion Lymphoma
P-03	Hiroki Goto [Kumamoto Univ.]	Targeting IL-6 in the crosstalk between HIV-1 infection and primary effusion lymphoma
P-04	Eriko Kudo [Kumamoto Univ.]	HIV-1 restriction factor, Murr1 (COMMD1), suppresses Toll-like receptor signaling in HIV-1 latently infected cells
P-05	Farzana Bhuyan [Kumamoto Univ.]	Features of HIV-1 replication in fibrocytes, the recently identified target cells of HIV-1
P-06 O-18-3A	Md Abu Osman [Kumamoto Univ.]	M-CSF diminishes anti-HIV-1 activity of cytokines including IL-32
P-07	Hesham E. Nasser [Kumamoto Univ.]	Phenotypes of fibrocytes, the recently identified HIV-1 host cells
P-08	Michihiro Hashimoto [Kumamoto Univ.]	The selective activation of anti-inflammatory M2-type macrophages by HIV-1 Nef is mediated by a serine/threonine kinase TAK1
P-09	Kodai Kawano [Kumamoto Univ.]	HIV-1 suppresses LINE-1 retrotransposition
P-10 O-33-3B	Kazuhiro Maeda [Kumamoto Univ.]	Role of mammalian TREX-2 component GANP in HIV-1 infection
P-11	Kazuaki Monde [Kumamoto Univ.]	HERV-K Gag coassembles with HIV-1 Gag via its CA domain and changes morphology of HIV-1 particles to reduce the infectivity
P-12	Yusuke Nakano [Kumamoto Univ.]	Preferential recognition of monomeric forms of CCR5 by HIV-1 envelope glycoprotein gp120 for the entry of R5 HIV-1
P-13	Hiromi Terasawa [Kumamoto Univ.]	Competitive resistance of a CXCR4-using HIV-1 lacking amino acid substitutions in the V3 loop of gp120 to a CXCR4 inhibitor AMD3100
P-14	Junko S Takeuchi [Kyoto Univ.]	Quantification of HIV cell-free and cell-to-cell transmissions based on experimental-mathematical investigations
P-15 O-19-3A	Kristel Paola Ramirez Valdez [Kumamoto Univ.]	Can antibodies contribute to controlling infection with transmitted/founder virus?

Poster No.	Presenter	Title
P-16	Kazuki Tanaka [Kumamoto Univ.]	Miniaturization of antibodies against CD4-induced epitope on gp120
P-17	Yasuhiro Maruta [Kumamoto Univ.]	Post-attachment neutralization as a mechanism of efficient activities of scFv from anti-V3 monoclonal antibody
P-18 O-34-3B	Muntasir Alam [Kumamoto Univ.]	Effects of Enfuvirtide resistant mutations on the sensitivity to neutralizing antibodies
P-19 O-28-3B	Shohei Taketomi [Tokyo Medical and Dental Univ.]	Structure activity relationship studies on a spacer moiety of small molecular CXCR4 antagonists as potent HIV-1 entry inhibitors
P-20	Yuki Hirota [Tokyo Medical and Dental Univ.]	Indole-type small CD4 mimic molecules targeting an HIV envelope protein gp120
P-21	Shigeyoshi Harada [NIID]	In vitro selection of bifunctional CD4 mimic small compounds (NBD analogues) using bulk and cloned primary isolates
P-22	Samatchaya Boonchawalit [Kumamoto Univ.]	Analysis of relationships between Maraviroc (MVC) resistant mutations and sensitivity to antibody-mediated neutralization
P-23 O-29-3B	Masayuki Amano [Kumamoto Univ.]	Discovery of small compounds which induce HIV-1 Capsid protein degradation
P-24	Tomofumi Nakamura [Kumamoto Univ.]	Dynamics of IN multimerization and a potent modulation by allosteric HIV-1 integrase (IN) inhibitors in living cells using bimolecular fluorescence complementation (BiFC)
P-25	Joseph R. Campbell [Kumamoto Univ.]	Accessing HIV-1 Integrase LEDGF Binding Inhibitors using bimolecular fluorescence complementation (BiFC)
P-26	Hiromi Ogata-Aoki [Kumamoto Univ.]	Prophylactic administration of Raltegravir alters dynamics of HIVmC dissemination in huPBMC-transplanted NOJ mice
P-27 O-31-3B	Amber R. Moore [Kumamoto Univ.]	Evaluation of HIV-1 reverse transcriptase (RT) heterodimerization within living cells using bimolecular fluorescence complementation (BiFC)
P-28 O-30-3B	Hironori Hayashi [Kumamoto Univ.]	The dimerization inhibition mechanism of darunavir and the dynamics of HIV-1 protease dimerization
P-29 O-32-3B	Pedro Miguel Salcedo Gómez [Kumamoto Univ.]	GRL-04810 and GRL-05010; novel difluoride-containing HIV-1 protease inhibitors (PIs) with potent antiviral activity and favorable penetration across the blood-brain barrier
P-30	Manabu Aoki [Kumamoto Health Science Univ.]	Novel HIV-1 protease inhibitors, GRL-015, GRL-085, and GRL-097, potently inhibit the replication of multi-PI-resistant HIV-1s
P-31 O-27-3A	Takayuki Chikata [Kumamoto Univ.]	Host-specific adaptation of HIV-1 subtype B in the Japanese population
P-32 O-22-3A	Xiaoming Sun [Kumamoto Univ.]	Presentation of two HLA-A*24:02-restricted overlapping epitopes elicit different patterns of CD8 T cell repertoire and select same escape mutation in HIV-infected patients

Poster No.	Presenter	Title
P-33 O-21-3A	Nozomi Kuse [Kumamoto Univ.]	Control of HIV-1 by Pol283-8-specific CTLs in HLA-B*51:01+long-term non progressors
P-34	Tomohiro Akahoshi [Kumamoto Univ.]	Reversion of a CTL escape mutation by escape mutant-specific CTLs
P-35	Zhansong Lin [Kumamoto Univ.]	Inhibition of human NK cell function by an HLA-Cw*12:02-restricted HIV-1 CTL epitope peptide and its escape mutant peptide
P-36	Tran Van Giang [Kumamoto Univ.]	Establishment of a cohort of treatment-naïve patients chronically infected with HIV-1 in Hanoi
P-37 O-25-3A	Keiko Sakai [Kumamoto Univ.]	The lack of a significant impact of HIV-1 Gag replication capacities on patients' disease outcomes in a chronically infected, treatment-naïve Japanese cohort
P-38	Mohammad Arif Rahman [Kumamoto Univ.]	Effect of protease inhibitor- and integrase inhibitor-resistant mutations on HIV-1-specific CTL recognition
P-39 O-24-3A	Macdonald Mahiti [Kumamoto Univ.]	Differential modulation of Nef-mediated downregulation activity of HLA class I alleles in HIV-1 chronic infection
P-40 O-26-3A	Stanley C. Meribe [Kumamoto Univ.]	Acceleration of disease Progression by a single naturally-arising polymorphism, within functional region of HIV-1 nef
P-41	Doreen Kamori [Kumamoto Univ.]	HLA-A*02 allelic variants differently influence amino acid polymorphisms in an immunodominant epitope of HIV-1 Vpr
P-42	Mako Toyoda [Kumamoto Univ.]	Analysis of naturally-occurring polymorphisms of HIV-1 Nef that impair CD4 down-regulation activity
P-43 O-20-3A	Chihiro Motozono [Kinki Univ.]	Molecular basis of a dominant T cell response to an HIV reverse transcriptase epitope presented by the protective allele HLA-B*51:01
P-44	Hiroshi Ishii [NIID]	Distinctive phenotype profiles of Env-specific CD8+ T cells in the chronic phase of SIV infection
P-45 O-23-3A	Koji Watanabe [NCGM]	Cross-clade CD8+ T cell responses in chronically HIV-1 clade A/E-infected individuals
P-46	Manthana Mitchai [Kumamoto Univ.]	HIV infection associated thrombocytopenia : a favourable clinical outcome in HAART therapy patient
P-47 O-36-3B	Junko Tanuma [NCGM]	Stably low prevalence of drug resistant HIV transmission while antiretroviral therapy was scaling up in Southern Vietnam: 2008-2012
P-48 O-37-3B	Kazuhiro Matsuoka [Nagoya Medical Center]	Cross-Resistance Mutation Patterns in Non-Nucleoside Reverse Transcriptase Inhibitors Rilpivirine and Etravirine in Clinical Isolates
P-49	Mayumi Imahashi [Nagoya Medical Center]	Dissociation between insertion/deletion polymorphisms of the APOBEC3B gene and HIV-1 risk: a population-based matched-cohort study in Japan

Poster No.	Presenter	Title
P-50	Takeshi Nishijima [NCGM/ Kumamoto Univ.]	Incidence and risk factors for incident hepatitis C infection among men who have sex with men with HIV-1 infection in a large urban HIV clinic in Tokyo
P-51	Masahiro Ishikane [NCGM]	Acute C hepatitis in Japanese HIV-infected patients in this decade
P-52	Daisuke Mizushima [NCGM/ Kumamoto Univ.]	Clinical utility of quantitative cytomegalovirus DNA and its kinetics for predicting cytomegalovirus end-organ disease in HIV-infected patients
P-53	Fumihide Kanaya [NCGM]	Monitoring of bone side effects during maraviroc containing treatment
P-54	Masaaki Toyama [Kagoshima Univ.]	A tetrahydrotetramethylbenzophenanthridinone derivative selectively inhibits the proliferation of adult T-cell leukemia (ATL) cell lines in vitro
P-55	Yohann White [University of the West Indies, Jamaica]	Impact of co-infection with human immunodeficiency virus type-1 and human T-cell lymphotropic virus type-1 on the latent HIV-1 reservoir in Jamaican patients with dual infection